Psyence Biomedical Ltd.
PBMHealthcare|Biotechnology|CA
$2.96
+0.02 (+0.68%)
DCF Value
$9.82
Tangible Book / Share
$30.68
Cash / Share
$13.48
Financials
Financial Snapshot
Market Cap
$56.3K
Enterprise Value
-$7.4M
Revenue (TTM)
$0.00
Net Income (TTM)
-$26.3M
Cash & Investments
$7.2M
Net Cash
$7.2M
Free Cash Flow (TTM)
-$1.1M
Operating CF (TTM)
-$1.1M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$7.2M
Quarterly Burn
$263.4K
Monthly Burn
$87.8K
Est. Runway
~27.3 quarters
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Investments | $431.9K | $16.0K | $762.8K | $6.1M | $7.4M | $7.2M | |
| Operating Cash Flow | -$839.2K | -$519.6K | -$2.9M | -$3.7M | -$8.1M | -$1.1M | |
| Free Cash Flow | -$839.2K | -$519.6K | -$3.0M | -$3.7M | -$8.6M | -$1.1M | |
| Capital Expenditure | $0.00 | $0.00 | -$5.7K | -$9.9K | -$500.2K | -$7.80 | |
| Financing Cash Flow | -$1.6M | $1.6K | $2.4M | $9.2M | $14.0M | -$245.8M |
R&D Spending
R&D (TTM)
$698.2K
R&D Intensity
—
R&D Growth vs Prior
-52.4%
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $137.2K | $1.6M | $954.6K | $342.2K | $1.5M | $698.2K | |
| SG&A | $1.7M | $1.6M | $1.8M | $3.3M | $4.8M | $2.8M |
Income Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $240.00 | $4.3K | $5.3K | $2.3K | |
| Gross Profit | $0.00 | $0.00 | -$240.00 | -$4.3K | -$5.3K | -$2.3K | |
| R&D | $137.2K | $1.6M | $954.6K | $342.2K | $1.5M | $698.2K | |
| SG&A | $1.7M | $1.6M | $1.8M | $3.3M | $4.8M | $2.8M | |
| Operating Income | -$334.3K | -$4.4M | -$2.8M | -$3.7M | -$6.2M | -$3.5M | |
| Interest Expense | $0.00 | $0.00 | $52.9K | $9.3K | $9.5K | $45.5K | |
| Pretax Income | $8.2M | $8.0M | -$51.2M | $1.0M | -$6.9M | -$25.7M | |
| Net Income | $8.2M | $8.0M | -$51.2M | $1.0M | -$6.9M | -$26.3M | |
| EPS (Diluted) | 0.25 | -0.64 | -7.85 | 1.78 | -12.56 | 1.62 | |
| EBITDA | $10.6M | $10.8M | -$51.1M | $1.0M | -$6.9M | -$2.1M | |
| Shares Out. (M) | 32.67 | 32.67 | 6.52 | 0.57 | 0.55 | 1.48 |
Balance Sheet
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $431.9K | $16.0K | $762.8K | $6.1M | $7.4M | $7.2M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $797.2K | $1.2M | $1.1M | $6.6M | $9.1M | $7.6M | |
| Total Assets | $326.6M | $258.9M | $1.1M | $7.3M | $17.6M | $12.8M | |
| Total Current Liabilities | $142.7K | $14.3M | $12.1M | $594.4K | $623.2K | $943.1K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $16.4M | $14.3M | $12.1M | $594.4K | $623.2K | $943.1K | |
| Stockholders' Equity | $236.6M | $244.7M | -$11.0M | $6.7M | $16.9M | $11.9M | |
| Retained Earnings | -$18.4M | -$13.9M | -$57.5M | -$56.4M | -$63.4M | -$58.4M |
Cash Flow Statement
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$839.2K | -$519.6K | -$2.9M | -$3.7M | -$8.1M | -$1.1M | |
| Capital Expenditure | $0.00 | $0.00 | -$5.7K | -$9.9K | -$500.2K | -$7.80 | |
| Free Cash Flow | -$839.2K | -$519.6K | -$3.0M | -$3.7M | -$8.6M | -$1.1M | |
| Investing Cash Flow | -$32.0K | $0.00 | -$5.7K | -$16.2K | -$4.5M | $246.8M | |
| Financing Cash Flow | -$1.6M | $1.6K | $2.4M | $9.2M | $14.0M | -$245.8M | |
| Issuance of Stock | $256.5M | $0.00 | $0.00 | $1.7M | $0.00 | $0.00 | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$247.4M | |
| Net Debt Issuance | $0.00 | $0.00 | $2.4M | $7.4M | $14.0M | $0.00 | |
| Stock Based Comp. | $332.1K | $221.3K | $317.9K | $0.00 | $155.3K | $158.94 | |
| Net Change in Cash | -$3.1M | -$565.00 | -$601.1K | $5.4M | $1.3M | -$40.4K |
Dilution Tracker
Shares Outstanding
0M
5-Year Share Growth
-98.3%
Stock Issuance (TTM)
$0.00
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 32.67 | 32.67 | 6.52 | 0.57 | 0.55 | 1.48 | |
| Change vs Prior % | — | 0.0% | -80.1% | -91.3% | -2.8% | 168.3% | |
| Stock Issuance | $256.5M | $0.00 | $0.00 | $1.7M | $0.00 | $0.00 | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$247.4M | |
| Stock Based Comp. | $332.1K | $221.3K | $317.9K | $0.00 | $155.3K | $158.94 |
Margins & Profitability
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| ROE % | 3.5% | 3.3% | 466.2% | 15.1% | -40.9% | -58.6% | |
| ROA % | 2.5% | 3.1% | -4518.7% | 13.8% | -39.5% | -39.5% | |
| ROIC % | -0.1% | -1.8% | 524.5% | -54.5% | -36.8% | -36.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | 0.0% | -1678.3% | -23.4% | |
| Operating Income | 0.0% | 0.0% | -1208.8% | 37.1% | -33.1% | -70.3% | |
| Net Income | 0.0% | 0.0% | -2.6% | -738.3% | 102.0% | -785.6% | |
| EPS (Diluted) | 0.0% | 0.0% | -356.0% | -1126.6% | 122.7% | -805.6% | |
| Operating Cash Flow | 0.0% | 0.0% | 38.1% | -466.8% | -26.8% | -118.1% | |
| Free Cash Flow | 0.0% | 0.0% | 38.1% | -468.0% | -26.9% | -130.8% | |
| R&D Expense | 0.0% | 0.0% | 1072.3% | -40.7% | -64.2% | 328.6% | |
| SG&A Expense | 0.0% | 0.0% | -5.4% | 10.5% | 84.6% | 43.7% | |
| Total Assets | 0.0% | 6561.8% | -20.7% | -99.6% | 546.2% | 140.1% | |
| Book Value / Share | 0.0% | 0.0% | -21.1% | -122.5% | 802.9% | 159.3% | |
| Debt | 0.0% | 0.0% | 0.0% | 1425.2% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | -80.1% | -91.3% | -2.8% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.10
10Y Low / Med / High0.08 / 3861.04 / 4036.92
EV/EBITDA1.07
10Y Low / Med / High0.88 / 86370.64 / 91719.89
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$9.82
Tangible Book / Share
$30.68
Net Current Assets / Share
$446.26
Graham Net-Net
$12.84
Cash / Share
$13.48
| Metric | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| P/E Ratio | 111852.73 | -47229.99 | -457.45 | 14.16 | -0.20 | -0.24 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 3861.04 | 4036.92 | -2132.90 | 2.13 | 0.08 | 0.10 | |
| EV/EBITDA | 86370.64 | 91719.89 | -458.13 | 7.98 | 0.88 | 1.07 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-6.25
Distress
Piotroski F-Score
3
Weak